STOCK TITAN

Atreca to Present at Upcoming Virtual Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Atreca, a biotechnology company listed under NASDAQ: BCEL, will participate in several upcoming virtual investor conferences in November and December 2020. The events include the Cowen 2020 Next IO Summit on November 13, Stifel 2020 Virtual Healthcare Conference on November 18, and Evercore ISI 3rd Annual HealthCONx on December 2, where Atreca will discuss cancer target identification. Live audio webcasts of the presentations can be found on their website, with replays available for 90 days post-event.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

Cowen 2020 Next IO Summit
Friday, November 13, 2020
Fireside Chat time: 2:45 p.m. EST

Stifel 2020 Virtual Healthcare Conference
Wednesday, November 18, 2020
Fireside Chat time: 4:40 p.m. EST

Evercore ISI 3rd Annual HealthCONx
Wednesday, December 2, 2020
Panel Discussion time: 10:30 a.m. EST
Title: “Finders Keepers: Identifying New Cancer Targets”

Live audio webcasts of the Cowen and Stifel presentations can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. An archived replay of each webcast will be available on the company's website for 90 days following the live presentations.

About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

Contacts
Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com

Investors:
Alex Gray, 650-779-9251
agray@atreca.com

Media:
Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com
Source: Atreca, Inc.

FAQ

When will Atreca participate in the Cowen 2020 Next IO Summit?

Atreca will participate in the Cowen 2020 Next IO Summit on November 13, 2020, with a fireside chat at 2:45 p.m. EST.

What is the date of the Stifel 2020 Virtual Healthcare Conference for Atreca?

The Stifel 2020 Virtual Healthcare Conference, where Atreca will participate, is scheduled for November 18, 2020, at 4:40 p.m. EST.

What will Atreca discuss at the Evercore ISI 3rd Annual HealthCONx?

Atreca will discuss cancer target identification in a panel titled 'Finders Keepers' at the Evercore ISI 3rd Annual HealthCONx on December 2, 2020, at 10:30 a.m. EST.

Where can I find the webcasts for Atreca's presentations?

Live audio webcasts of Atreca's presentations can be accessed in the Events & Presentations section of their website.

How long will Atreca's webcast replays be available?

Archived replays of Atreca's webcasts will be available for 90 days following each live presentation.

ATRECA INC A

OTC:BCEL

BCEL Rankings

BCEL Latest News

BCEL Stock Data

3.57M
27.54M
2.68%
8.39%
0.69%
Biotechnology
Healthcare
Link
United States of America
San Carlos